AChE

Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...


The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...


The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in...


The FDA ( U.S. Food and Drug Administration ) has approved Isturisa ( Osilodrostat ) oral tablets for adults with...


COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...


The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia...


Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...


First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell...


Ibrutinib ( Imbruvica ) has shown single-agent activity in relapse / refractory ( R/R ) primary central nervous system lymphoma...


Erdafitinib ( Balversa ) is a pan-FGFR kinase inhibitor for treatment of adults with metastatic urothelial carcinoma ( mUC )...


Acalabrutinib ( Calquence ) is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic...


Pembrolizumab ( Keytruda ) was approved for the treatment of high-risk ( HR ) non–muscle-invasive bladder cancer ( NMIBC )...


Papillary renal cell carcinoma ( PRCC ) is the most common type of non-clear cell RCC, accounting for 10–15% of...


The highly selective TRK inhibitor Larotrectinib ( Vitrakvi ) is approved for the treatment of adult and pediatric cancers that...


Cemiplimab ( Libtayo ) monotherapy achieves clinically meaningful activity in patients with advanced cutaneous squamous cell carcinoma ( CSCC )...